<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-one patients (20 male and 11 female; median age 51 years (16-79)) with high-risk <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (20 refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 11 secondary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (four to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, five to chemo/radiotherapy, one to <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and one blastic <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (B-<z:mp ids='MP_0005481'>CML</z:mp>)) were treated with CBDCA (300 mg/m2/day x 5 days in continuous i.v </plain></SENT>
<SENT sid="1" pm="."><plain>infusion) plus intermediate-dose Ara-C (500 mg/m2/day x 3 days in rapid i.v </plain></SENT>
<SENT sid="2" pm="."><plain>infusion) </plain></SENT>
<SENT sid="3" pm="."><plain>Nine patients (29%) achieved CR (five s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (three <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, one <z:mp ids='MP_0005481'>CML</z:mp> and one ALL) and four refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 11 patients had resistant disease </plain></SENT>
<SENT sid="4" pm="."><plain>There were 11 early <z:hpo ids='HP_0011420'>deaths</z:hpo> (35%) </plain></SENT>
<SENT sid="5" pm="."><plain>Median disease-free survival of the nine responders was 4 months </plain></SENT>
<SENT sid="6" pm="."><plain>The main toxicity was hematological, febrile episodes took place in nearly <z:hpo ids='HP_0000001'>all</z:hpo> the patients (96%) </plain></SENT>
<SENT sid="7" pm="."><plain>The CBDCA plus Ara-C regimen showed an evident antileukemic activity in high-risk <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>However, the lack of long-term disease-free survivors shows the need for innovative postremission strategies </plain></SENT>
<SENT sid="9" pm="."><plain>The high initial response rate seen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) warrants further investigation of CBDCA in combination regimens for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>